Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
15 pending office actions • 10 art units • 15 examiners • 0 of 15 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
The UAB Research Foundation is currently managing a significant volume of 15 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are spread across 15 distinct examiners, showing a high degree of diversification in the individuals reviewing the company's applications. These examiners are distributed among 10 distinct art units, which indicates that the foundation's research covers a broad range of technical disciplines. This wide distribution requires a sophisticated management strategy to ensure consistency across 10 distinct art units.
POPA, ILEANA is the busiest examiner for this portfolio, currently handling 1 pending office action. Despite the large total of 15 pending office actions, the workload is perfectly distributed among the 15 distinct examiners, with each examiner responsible for 1 pending matter. This suggests that the foundation's prosecution is not concentrated under any single examiner's discretion. For practitioners, this means that the foundation is engaged in numerous independent dialogues with the patent office, reducing the impact of any 1 examiner's tendencies.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (7%) |
| §103 only | 4 (27%) |
| Double-patenting only | 1 (7%) |
| Multi-statute (no §101) | 9 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POPA, ILEANA | 1 | 21.4% | +15.1% |
| WINAKUR, ERIC FRANK | 1 | 79.3% | +13.8% |
| HAMA, JOANNE | 1 | 25.7% | +40.0% |
| LEE, EDMUND H | 1 | 69.6% | +17.5% |
| TRA, TUYEN Q | 1 | 85.6% | +9.2% |
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
| SCHWECHTER, BRANDON ROSS | 1 | 0.0% | +0.0% |
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| SISON, CHRISTINE ANDREA PAN | 1 | 33.3% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18958046 | Compositions and Methods for Cancer Immunotherapy | POPA, ILEANA | — |
| 18867687 | DEVICES AND METHODS FOR TRANSCUTANEOUS BILIRUBIN MEASUREMENT | WINAKUR, ERIC FRANK | — |
| 18865259 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | HAMA, JOANNE | — |
| 18836134 | AN ANTI-MYOPIA VISUAL DISPLAY THERAPY USING SIMULATED MYOPIC BLUR | TRA, TUYEN Q | — |
| 18730565 | COMPOSITIONS AND METHODS OF REGENERATING HEART TISSUES WITH AMINOGLYCOSIDES | BERRY, LAYLA D | — |
| 18667950 | GENERATION OF S-NITROSOACETYLCYSTEINE | KWON, YONG SOK | — |
| 18700751 | BMP9 OR AN AGONIST THEREOF AND ITS USES RELATED TO REDUCING METASTASIS OF CANCER | SCHWECHTER, BRANDON ROSS | — |
| 18690101 | METHODS AND FORMULATIONS RELATED TO THE INTRATHECAL DELIVERY OF ONCOLYTIC VIRUSES | MATALKAH, FATIMAH KHALAF | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18337705 | SELECTIVE STIMULATION OF GROUPS OF NEURAL ELEMENTS WITHIN A REGION OF THE BRAIN | SISON, CHRISTINE ANDREA PAN | 60d overdue |
| 18958046 | Compositions and Methods for Cancer Immunotherapy | POPA, ILEANA | — |
| 18867687 | DEVICES AND METHODS FOR TRANSCUTANEOUS BILIRUBIN MEASUREMENT | WINAKUR, ERIC FRANK | — |
| 18865259 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | HAMA, JOANNE | — |
| 18915925 | INORGANIC FIBER TUBULAR STRUCTURES, AND SYSTEM AND METHOD FOR MANUFACTURING THE INORGANIC FIBER TUBULAR STRUCTURES | LEE, EDMUND H | — |
| 18667950 | GENERATION OF S-NITROSOACETYLCYSTEINE | KWON, YONG SOK | — |
| 18690101 | METHODS AND FORMULATIONS RELATED TO THE INTRATHECAL DELIVERY OF ONCOLYTIC VIRUSES | MATALKAH, FATIMAH KHALAF | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 1645 | 1 |
| 1744 | 1 |
| 1638 | 1 |
| 3796 | 1 |
| 1637 | 1 |
| 3785 | 1 |
| 1614 | 1 |
| 2872 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18958046 | Compositions and Methods for Cancer Immunotherapy | POPA, ILEANA | 1633 | §103§112Other | Non-Final OA | — | Pending | Nov 25, 2024 |
| 18867687 | DEVICES AND METHODS FOR TRANSCUTANEOUS BILIRUBIN MEASUREMENT | WINAKUR, ERIC FRANK | — | §102§103§112 | Non-Final OA | — | Pending | Nov 20, 2024 |
| 18865259 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | HAMA, JOANNE | 1645 | §102§103 | Non-Final OA | — | Pending | Nov 12, 2024 |
| 18915925 | INORGANIC FIBER TUBULAR STRUCTURES, AND SYSTEM AND METHOD FOR MANUFACTURING THE INORGANIC FIBER TUBULAR STRUCTURES | LEE, EDMUND H | 1744 | DP | Final Rejection | — | Pending | Oct 15, 2024 |
| 18836134 | AN ANTI-MYOPIA VISUAL DISPLAY THERAPY USING SIMULATED MYOPIC BLUR | TRA, TUYEN Q | — | §102§103 | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18730565 | COMPOSITIONS AND METHODS OF REGENERATING HEART TISSUES WITH AMINOGLYCOSIDES | BERRY, LAYLA D | — | §102§103 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18667950 | GENERATION OF S-NITROSOACETYLCYSTEINE | KWON, YONG SOK | — | §102§103§112 | Non-Final OA | — | Pending | May 17, 2024 |
| 18700751 | BMP9 OR AN AGONIST THEREOF AND ITS USES RELATED TO REDUCING METASTASIS OF CANCER | SCHWECHTER, BRANDON ROSS | — | §103§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18690101 | METHODS AND FORMULATIONS RELATED TO THE INTRATHECAL DELIVERY OF ONCOLYTIC VIRUSES | MATALKAH, FATIMAH KHALAF | 1638 | §103§112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18337705 | SELECTIVE STIMULATION OF GROUPS OF NEURAL ELEMENTS WITHIN A REGION OF THE BRAIN | SISON, CHRISTINE ANDREA PAN | 3796 | §103 | Final Rejection | 60d overdue | Pending | Jun 20, 2023 |
| 18315677 | PRE-CLINICAL MODIFIED RNA APPROACHES USED IN LARGE ANIMALS FOR MUSCLE AND VASCULAR REGENERATION | ALLEN, SARAH ELIZABETH | 1637 | §103 | Final Rejection | 16d overdue | Pending | May 11, 2023 |
| 18022230 | GENERATION OF NITRIC OXIDE AND DELIVERY SYSTEMS | RAUBENSTRAW, TYLER ALLEN | 3785 | §103§112 | Non-Final OA | — | Pending | Feb 20, 2023 |
| 17765926 | MULTI-LAYERED NANOPARTICLE COATED SUBSTRATES FOR DRUG DELIVERY | PARK, HAEJIN S | 1614 | §103 | Final Rejection | 162d overdue | Pending | Apr 01, 2022 |
| 17761806 | MULTI-SPECTRAL AND MULTI-FOCAL CONTROL OF MYOPIA | WILKES, ZACHARY W | 2872 | §101§102§112 | Non-Final OA | — | Pending | Mar 18, 2022 |
| 17479453 | METHOD FOR INCREASING CELL SUSCEPTIBILITY TO COMPLEMENT- MEDIATED LYSIS | COOK, LISA V | 1642 | §103 | Non-Final OA | — | Pending | Sep 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial